14
Views
1
CrossRef citations to date
0
Altmetric
Review

Appraisal of the multiple sclerosis functional composite

&
Pages 335-341 | Published online: 10 Jan 2014

References

  • Cutter GR, Baier ML, Rudick RA et al Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122, 871–882 (1999).
  • •Description of the methods used to develop the MSFC.
  • Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1, 37–47 (1995).
  • Rudick R, Antel J, Confavreux C et at. Clinical outcomes assessment in multiple sclerosis. Ann Neutvl 40, 469–479 (1996).
  • Wingerchuk DM, Noseworthy JH, Weinshenker BG. Clinical outcome measures and rating scales in multiple sclerosis trials. Nivo Clinic Pmceerlings 72, 1070–1079 (1997).
  • Kurtzke JE The evaluation of disability in multiple sclerosis. Neurology 11, 686–694 (1961).
  • Kurtzke JE Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33, 1444–1452 (1983).
  • Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing Functional Systems and disability on the Kurtzke Scale in multiple sclerosis. Airh. Neural 45, 746–748 (1998).
  • Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 40, 971–975 (1990).
  • Hohol MJ, Orav EJ, Weiner HL. Disease Steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 45, 251–255 (1995).
  • Sipe JC, Knobler RL, Braheny SL, Rice GPA, Panitch HS, Oldstone MBA. A neurologic rating scale ( NRS) for use in multiple sclerosis. Neurology 34, 1368–1372 (1984). itHauser SL, Dawson DM, Lehrich JR etal Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose iv. cyclophosphamide, plasma exchange and ACTH. N Eng. I Med. 308, 173–180 (1983).
  • Tourtellotte WW Haerer AE Simpson JF, Kuzma JW Quantitative clinical neurological testing I. A study of a battery of tests designed to evaluate in part the neurological function of patients with multiple sclerosis and its use in a therapeutic trial. Ann. NIL Acad. Sri. 122, 480–505 (1965).
  • Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Administration and scoring Manual for the Multiple Sclerosis Functional Composite measum (MSFC): National Multiple Sclerosis Society, 2001.
  • Cohen JA. Intrarater and interrater reliability of the MS functional composite outcome measure. Neumlogy54, 802–806 (2000).
  • Cohen JA, Cutter GR, Fischer JS etal Use of the multiple sclerosis functional composite as an outcome measure in a Phase 3 clinical trial. Arch. Neural 58, 961–967 (2001).
  • Fischer JS, Rudick RA, Cutter GR, REingold SC. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Multiple Sclerosis 5, 244–250 (1999).
  • •Discusses the initial efforts to validate the MSFC.
  • Kalkers NF, de Groot V, Lazeron RHC et al. MS Functional Composite: relation to disease phenotype and disability strata. Neurology 54, 1233–1239 (2000).
  • Rudick RA, Cutter G, Baier M eta]. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology56, 1324–1330 (2001).
  • Kalkers NE Bergers L, de Groot V eta]. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology56, 215–219 (2001).
  • Miller DM, Rudick RA, Cutter G, Baier M, Fischer J. Clinical significance of the Multiple Sclerosis Functional Composite: relationship to patient-reported quality of life. Arch. Neural 57, 1319–1324 (2000).
  • Ma S-L, Shea JA, Galetta SL et al Self- reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am. j Ophthalmol 133, 686–692 (2002).
  • Baker LJ, Baier ML, Pelak VS etal New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Multiple Sclerosis 6, 163–171 (2000).
  • Balcer LJ, Baier ML, Kooijmans M eta]. Low-Contrast Sloan Letter Chart Testing as a candidate visual outcome measure for the Multiple Sclerosis Functional Composite (MSFC). Neurology58, S3–513 (2002).
  • Comparison of visual function tests in an MS cohort. North American Neuro-Ophthalmology Society Annual Meeting. Snowbird, UT, USA. 9–14 February (2003).
  • Fisk JD, Archibald CJ. Limitations of the Paced Auditory Serial Addition Test as a measure of working memory in patients with multiple sclerosis. J: Int. Neuropsychol Soc. 7, 363–372 (2001).
  • Snyder PJ, Cappelleri JC. Information processing speed deficits may be better correlated with the extent of white matter sclerotic lesions in multiple sclerosis than previously suspected. Brain Cog. 46, 279–284 (2000).
  • Snyder PJ, Cappelleri JC, Archibald CJ, Fisk JD. Improved detection of differential information-processing speed deficits between two disease-course types of multiple sclerosis. Neuropsychology15, 617–625 (2001).
  • Cohen JA, Cutter GR, Fischer JS etal Benefit of interferon beta-la on MSFC progression in secondary progressive MS. Neurology59, 679–687 (2002).
  • Schwid SR, Goodman AD, McDermott MP Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neumlogy58, 1294–1296 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.